On June 13, 2014, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), announced the presentation of data from a phase III study and long-term extension studies on Kalydeco at the 37th European Cystic Fibrosis Society (ECFS) conference. The studies evaluated Kalydeco in patients suffering from cystic fibrosis (CF) having the G551D mutation. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), net profit margin is -36.90% . On last trading day company shares ended up $73.49. Analysts mean target price for the company is $90.45. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), distance from 50-day simple moving average (SMA50) is 7.66%.
On June 16, 2014, Clovis Oncology Inc (NASDAQ:CLVS), announced that the RUCAPANC (Rucaparib Assessment in BRCA-mutated Pancreatic Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the Company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of pancreatic cancer and platinum-sensitive ovarian cancer. Clovis Oncology Inc (NASDAQ:CLVS), advanced 1.73% in last trading session and ended the day on $45.29. CLVS, return on assets is -19.80%. Clovis Oncology Inc (NASDAQ:CLVS), quarterly performance is -44.36%.
Caesars Entertainment Corp (NASDAQ:CZR), is one of the most established casino operators in the United States. It saw remarkable growth over the course of 2013 but in this first half of 2014, Caesars Entertainment Corp has been in a bit of a slump. The stock is down but not out. Recent moves into global markets as well as online gambling should play out well for the company and revitalize the stock. Caesars Entertainment Corp (NASDAQ:CZR), shares moved up 2.56% in last trading session and was closed at $18.05, while trading in range of $17.25 – 18.31. Caesars Entertainment Corp (NASDAQ:CZR), year to date (YTD) performance is -16.20%.
Karyopharm Therapeutics Inc (NASDAQ:KPTI), announced initial Phase 1 data from patients with multiple myeloma treated with Selinexor, in combination with “low-dose” dexamethasone Friday morning. Karyopharm Therapeutics Inc (NASDAQ:KPTI), ended the last trading day at $47.12. Company weekly volatility is calculated as 22.14% and price to cash ratio as 9.68. Karyopharm Therapeutics Inc (NASDAQ:KPTI), showed a negative weekly performance of 87.21%.
After Gilead Sciences, Inc. (NASDAQ:GILD), stock fell following Merck’s (MRK) acquisition of Idenix (IDIX), RBC Capital expects Sovaldi sales to come in well above consensus estimates for 2015, potentially enabling Gilead’s EPS to reach $8-$10. RBC Capital says that the market expects the sales of HCV treatments to drop significantly in 2016, but the firm does not agree with this outlook. RBC Capital keeps an Outperform rating on Gilead. Gilead Sciences, Inc. (NASDAQ:GILD), net profit margin is 33.50% and weekly performance is -2.03%. On last trading day company shares ended up $80.72. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD), distance from 50-day simple moving average (SMA50) is 4.64%.
Leave a Reply